Condition: Advanced Renal Cell Carcinoma (aRCC) · Metastatic Renal Cell Carcinoma ( mRCC) · Clear Cell Renal Cell Carcinoma (ccRCC) · Sponsor: Brian Rini
This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.
This description comes directly from the study's public registry record.
Brian Rini, MD · 615-936-8422 · brian.rini@vumc.org
Allison Lipps · 317-634-5842 · alipps@hoosiercancer.org
Always discuss trial participation with your own doctor first.
| Vanderbilt-Ingram Cancer Center | Nashville, Tennessee, United States | Recruiting |
| Froedtert and The Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07188896